Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.94 USD | +0.18% | +0.52% | +240.69% |
09:33pm | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
09/05 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.69% | 4.25B | |
+3.99% | 108B | |
+11.10% | 104B | |
+1.28% | 22.33B | |
-12.93% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.43% | 17.64B | |
+3.57% | 14.05B | |
+36.99% | 12.51B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal